Clinical Trial Update: PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a PD-1 inhibitor in combination with Pyrotinib for chemotherapy-refractory non-small cell lung cancer with HER2 insertion mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PD-1 inhibitor
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Yongchang Zhang | Conditions: HER2 Insertion Mutation Positive Advanced NSCLC | Phase 2 | Status: RECRUITING